ES2506116T3 - Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo - Google Patents

Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo Download PDF

Info

Publication number
ES2506116T3
ES2506116T3 ES09749849.7T ES09749849T ES2506116T3 ES 2506116 T3 ES2506116 T3 ES 2506116T3 ES 09749849 T ES09749849 T ES 09749849T ES 2506116 T3 ES2506116 T3 ES 2506116T3
Authority
ES
Spain
Prior art keywords
trem
sepsis
subject
sample
prognosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09749849.7T
Other languages
English (en)
Inventor
Koen Kas
Griet Vanpoucke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biocartis NV
Original Assignee
Biocartis NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocartis NV filed Critical Biocartis NV
Application granted granted Critical
Publication of ES2506116T3 publication Critical patent/ES2506116T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Método para la predicción, pronóstico y/o diagnóstico de septicemia, septicemia grave, choque septicémico, o MODS en un sujeto de prueba que comprende: (a) medir el nivel de transcrito de receptor similar a TREM-1 soluble (sTLT1) y TREM-1 en una muestra de sangre o suero extraída de dicho sujeto de prueba, y (b) comparar dicho nivel de transcrito de receptor similar a TREM-1 soluble (sTLT1) y TREM-1 con un nivel de referencia de transcrito de receptor similar a TREM-1 soluble (sTLT1) y TREM-1 obtenido de una muestra de un sujeto sano, en la que (c) un nivel de expresión reducida de sTLT-1 y una expresión aumentada de TREM-1 en la muestra del sujeto de prueba en comparación con los de una muestra de un sujeto sano o sin septicemia indica que el sujeto de prueba tiene o corre el riesgo de tener septicemia, septicemia grave, choque septicémico o MODS.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17

Claims (1)

  1. imagen1
    imagen2
ES09749849.7T 2008-05-23 2009-05-19 Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo Active ES2506116T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08156837 2008-05-23
EP08156837 2008-05-23
PCT/EP2009/056094 WO2009141359A1 (en) 2008-05-23 2009-05-19 New biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof

Publications (1)

Publication Number Publication Date
ES2506116T3 true ES2506116T3 (es) 2014-10-13

Family

ID=40897625

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09749849.7T Active ES2506116T3 (es) 2008-05-23 2009-05-19 Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo

Country Status (5)

Country Link
US (1) US8697370B2 (es)
EP (2) EP2796878A1 (es)
CA (1) CA2721742A1 (es)
ES (1) ES2506116T3 (es)
WO (1) WO2009141359A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2010132370A2 (en) * 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
US20120089421A1 (en) * 2010-10-08 2012-04-12 Cerner Innovation, Inc. Multi-site clinical decision support for sepsis
WO2012136548A1 (en) 2011-04-04 2012-10-11 Universiteit Gent Biomarkers for acute kidney injury
RU2463606C1 (ru) * 2011-08-17 2012-10-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний Сибирского отделения Российской академии медицинских наук (УРАМН НИИ КПССЗ СО РАМН) Способ ранней диагностики осложненного системного воспалительного ответа у пациентов, оперированных в условиях искусственного кровообращения
WO2013119869A1 (en) * 2012-02-07 2013-08-15 Children's Hospital Medical Center A multi-biomarker-based outcome risk stratification model for adult septic shock
US9238841B2 (en) 2012-02-07 2016-01-19 Children's Hospital Medical Center Multi-biomarker-based outcome risk stratification model for pediatric septic shock
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
US9000127B2 (en) 2012-02-15 2015-04-07 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
EP2814842B1 (en) 2012-02-15 2018-08-22 Novo Nordisk A/S Antibodies that bind peptidoglycan recognition protein 1
CA2893158A1 (en) * 2012-11-30 2014-06-05 Applied Proteomics, Inc. Method for evaluation of presence of or risk of colon tumors
CA2915611A1 (en) * 2013-06-28 2014-12-31 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
EP3030576A4 (en) * 2013-08-07 2017-04-05 University Of Rochester Method of diagnosing sepsis or sepsis risk
EP3074536B1 (en) 2013-11-25 2019-06-19 Children's Hospital Medical Center Temporal pediatric sepsis biomarker risk model
KR101569334B1 (ko) 2013-12-20 2015-11-17 경북대학교 산학협력단 래프틀린을 함유하는 패혈증 진단용 바이오마커 조성물 및 이를 이용한 진단방법
US10260111B1 (en) 2014-01-20 2019-04-16 Brett Eric Etchebarne Method of detecting sepsis-related microorganisms and detecting antibiotic-resistant sepsis-related microorganisms in a fluid sample
SG11201700250WA (en) 2014-07-17 2017-02-27 Novo Nordisk As Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
CA2954601C (en) 2014-08-14 2023-04-18 Memed Diagnostics Ltd. Computational analysis of biological data using manifold and a hyperplane
US10761093B2 (en) 2014-10-09 2020-09-01 Texas Tech University System Microdevice for cell separation utilizing activation phenotype
WO2016059636A1 (en) 2014-10-14 2016-04-21 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
WO2016092554A1 (en) * 2014-12-11 2016-06-16 Memed Diagnostics Ltd. Marker combinations for diagnosing infections and methods of use thereof
JP2018517892A (ja) 2015-04-10 2018-07-05 アプライド プロテオミクス，インク． 結腸直腸癌と進行腺腫を検知するためのタンパク質バイオマーカーパネル
US10261068B2 (en) 2015-06-04 2019-04-16 Children's Hospital Medical Center Persevere-II: redefining the pediatric sepsis biomarker risk model with septic shock phenotype
CA2989381A1 (en) 2015-07-15 2017-01-19 Universiteit Gent Probes and a methylation in situ hybridization assay
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
EP4141448A1 (en) 2016-07-10 2023-03-01 MeMed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP4184167A1 (en) 2016-07-10 2023-05-24 MeMed Diagnostics Ltd. Early diagnosis of infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
JP2021519594A (ja) 2018-04-02 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｔｒｅｍ−１抗体およびその使用
US11154240B2 (en) 2019-04-02 2021-10-26 Kpn Innovations Llc Methods and systems for utilizing diagnostics for informed vibrant constitutional guidance
WO2021123249A1 (en) * 2019-12-20 2021-06-24 Gerencia Regional de Salud de Castilla y León In vitro method for the differential diagnosis between septic shock and non-septic shock patients
US11289206B2 (en) 2020-06-02 2022-03-29 Kpn Innovations, Llc. Artificial intelligence methods and systems for constitutional analysis using objective functions
US11211158B1 (en) 2020-08-31 2021-12-28 Kpn Innovations, Llc. System and method for representing an arranged list of provider aliment possibilities
WO2023087016A1 (en) * 2021-11-15 2023-05-19 Ascendo Biotechnology, Inc. Methods to reverse treml1-induced immune suppression
CN117491284B (zh) * 2023-11-03 2024-05-07 上海长征医院 一种基于微流控技术的脓毒症即时检测设备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US20040180409A1 (en) 2003-03-16 2004-09-16 Mcvicar Daniel TLT-1, a novel platelet-associated receptor and uses therefor
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
AU2006299417A1 (en) 2005-10-03 2007-04-12 Biosite Incorporated Methods and compositions for diagnosis and/or prognosis in Systemic Inflammatory Response Syndromes

Also Published As

Publication number Publication date
US20110059858A1 (en) 2011-03-10
EP2300829A1 (en) 2011-03-30
US8697370B2 (en) 2014-04-15
WO2009141359A1 (en) 2009-11-26
EP2796878A1 (en) 2014-10-29
CA2721742A1 (en) 2009-11-26
EP2300829B1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
ES2506116T3 (es) Nuevo biomarcador para diagnóstico, predicción y/o pronóstico de septicemia y usos del mismo
ES2656150T3 (es) Diagnóstico de la sepsis y del síndrome de respuesta inflamatoria sistémica
ES2484142T3 (es) Diagnóstico molecular y clasificación del melanoma maligno
AR060121A1 (es) Medio y metodo para predecir la diabetes
ES2656962T3 (es) Métodos para evaluar la receptividad del endometrio de una paciente
BR112014013082A2 (pt) método para detectar adutos nucleossomos
NZ593514A (en) p-mTOR and p-AKT as Ratio Based Biomarkers for the Prognosis and/or Diagnosis of Cancer
NZ600828A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
NZ599105A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
GB2467704A (en) Methods of monitoring conditions by sequence analysis
BR112013003391B8 (pt) Método para diagnosticar câncer pancreático em um indivíduo
BR112012019542A2 (pt) "método para avaliar o estado renal em um indivíduo, medição de um ou mais biomarcadores, e, kit"
BRPI1007867B8 (pt) anticorpo recombinante ou fragmento de ligação ao antígeno do mesmo, composição farmacêutica e kit compreendendo o referido anticorpo, métodos de detecção de antígeno de troponina i em uma amostra de teste e métodos in vitro de diagnóstico de síndrome coronariana aguda ou infarto do miocárdio em um paciente
RU2009139295A (ru) Биомаркеры и биомаркерные признаки почечной сохранности, обладающие предсказательной силой, для использования в мониторинге состояния почек
ES2570632T3 (es) Procedimiento de determinación del inhibidor de elastasa de leucocito in vitro del cáncer colorrectal
BR112014006741A2 (pt) método para monitorização, diagnóstico e/ou prognóstico de lesão renal aguda no estágio inicial
ES2570627T3 (es) Ensayo in vitro de Ezrina para el diagnóstico del cáncer colorrectal
EP3159695A3 (en) Methods for diagnosing pancreatic cancer
Cypen et al. Novel biomarkers for the risk stratification of heart failure with preserved ejection fraction
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
AR087363A1 (es) Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
ZA202102071B (en) Use of soluble trem-1 levels for identifying subjects susceptible to respond to an anti-inflammatory therapy
PE20120592A1 (es) Metodo con biomarcadores para el seguimiento de un tratamiento
ES2488628T3 (es) Terapia de combinación y método de evaluación de la resistencia a un tratamiento
ES2544984T3 (es) Detección de la descomposición de enzimas en un elemento de ensayo por liberación controlada de un analito protegido